Tolvaptan, hyponatremia, and heart failure
Hammam D Zmily1, Suleiman Daifallah2, Jalal K Ghali31Wayne State University/Detroit Medical Center, Detroit, MI, USA; 2John D Dingell VA Medical Center, Detroit, MI, USA; 3Detroit Medical Center, Detroit, MI, USAAbstract: Tolvaptan is the first FDA-approved oral V2 receptor antagonist for the treatm...
Main Authors: | Zmily HD, Daifallah S, Ghali JK |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-03-01
|
Series: | International Journal of Nephrology and Renovascular Disease |
Online Access: | http://www.dovepress.com/tolvaptan-hyponatremia-and-heart-failure-a6893 |
Similar Items
-
Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients
by: Savina Nodari, et al.
Published: (2010-05-01) -
Tolvaptan for treatment of iatrogenic hyponatremia
by: Dhaval Shukla
Published: (2016-01-01) -
Tolvaptan and its potential in the treatment of hyponatremia
by: Y Howard Lien, et al.
Published: (2008-10-01) -
Tolvaptan vs. furosemide‐based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA‐AHF)
by: Tien M.H. Ng, et al.
Published: (2020-08-01) -
Effect of tolvaptan on acute heart failure with hyponatremia – A randomized, double blind, controlled clinical trial
by: Elangovan Shanmugam, et al.
Published: (2016-04-01)